AstraZeneca's Strong First Quarter Includes Significant Emerging Markets Growth
This article was originally published in The Pink Sheet Daily
In China alone, the Big Pharma notes net sales were up 36 percent year over year.
You may also be interested in...
AZ's emerging markets strategy includes selective entry into branded generics
Innovation-only AstraZeneca gets the branded generics religion, at least in emerging markets.
Facing a raft of patent expiries, AstraZeneca pays richly for Rigel's Phase II oral RA candidate.